Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats

Youxue Wang, Satoru Naruse, Motoji Kitagawa, Hiroshi Ishiguro, Yasuyuki Nakae, Toshiyuki Yoshikawa, Tetsuo Hayakawa

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The effects of a new benzodiazepine-derivative, cholecystokinin receptor antagonist, TS-941, on experimental acute pancreatitis were studied in rats. Hemorrhagic pancreatitis was induced by an infusion of a mixture of trypsin and taurocholate into the pancreatic duct. Edematous pancreatitis was induced by intraperitoneal injection of 40 μg/kg body weight of cerulein at 0 and 1 h after the start of the experiment. TS-941 (3 mg/kg) was injected subcutaneously immediately and 3 h after the induction of pancreatitis. In trypsin-taurocholate-induced pancreatitis, TS-941, with or without the synthetic trypsin inhibitor ONO-3403, had no beneficial effects on the survival rate, pancreatic wet weight, and serum pancreatic enzymes. In cerulein-induced pancreatitis, the treatment with TS-941 significantly reduced the increases of pancreatic wet weight and serum amylase and lipase. Plasma trypsinogen activation peptide (TAP) significantly rose 1 h after the first injection of cerulein. TS-941 inhibited the liberation of TAP in cerulein-induced pancreatitis. These results show that TS-941 is effective for prevention of cerulein-induced edematous pancreatitis. ONO-3403 has beneficial effects on trypsin-taurocholate-induced hemorrhagic pancreatitis, but the combination of TS-941 and ONO-3403 has no additive effect.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
Issue number3
StatePublished - Oct 1998


  • Cholecystokinin receptor antagonist
  • Experimental pancreatitis
  • Trypsinogen activation peptide (TAP)
  • α macroglobulin trypsin complex

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology


Dive into the research topics of 'Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats'. Together they form a unique fingerprint.

Cite this